News and Trends 31 Oct 2019 European Project Launches to Tailor Autoimmune Disease Treatments Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […] October 31, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 7 Aug 2019 Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience In less than two years, Orchard Therapeutics has changed from a small, relatively unknown UK biotech specializing in gene therapy into a billion euro company listed on the Nasdaq. This is in no small part due to the skills and experience of Mark Rothera, its CEO and President, who joined the company in 2017. Orchard […] August 7, 2019 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2019 EU Approves Two-Drug Pill as First-Line Treatment for HIV The two-drug pill Dovato, developed by the UK company ViiV Healthcare, has been approved as a first-line treatment for HIV, potentially causing fewer long-term side effects than current three-drug antiretroviral regimens. HIV patients currently need to take three or more antiretroviral drugs per day to keep the infection at bay. As they get older, these […] July 3, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2019 Update: Two-Drug HIV Treatment Effective for up to Three Years Update (04/04/2019): ViiV Healthcare’s two-drug HIV treatment, Juluca, has successfully suppressed the HIV virus for up to three years in patients’ blood. In a clinical study, 513 HIV-infected people switched to daily pills of Juluca from their standard drug regimes, which included three or four different drugs. Juluca was effective at suppressing the virus for […] April 4, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2018 Oxford Biotech Launches with €26M to Target ‘Immunometabolism’ Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […] October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 3 Sep 2018 Moving from Big Pharma to Biotech – Insights from Two Biotech CEOs According to John LaMattina in Forbes last year, more and more senior scientific executives are moving from pharma to small biotechs or startup initiatives. While the jury is out on whether this observation reflects a real trend or not, we at Labiotech are keen to learn about what drives people to make such a move! […] September 3, 2018 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2018 GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […] February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval Update (24/10/2017): Shingrix has been approved by the FDA and will cost $280 (€238) for the required two shots, which should be covered by most insurance plans. Originally published on 13/9/2017 An FDA panel voted 11-0 to support the approval of GSK’s new shingles vaccine based on “impressive” efficacy and safety results in a Phase III […] October 24, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2017 Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US A British-American collaboration’s once-daily triple therapy inhaler has been approved for use by appropriate COPD patients in the US. A new triple therapy inhaler for chronic obstructive pulmonary disease (COPD), Trelegy Ellipta, has been developed by British giant GSK in collaboration with Innoviva in the US. The inhaler is targeted at patients who are struggling with airflow […] September 20, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Infographics 13 Sep 2017 The 10 Most Innovative HIV Treatments to Defeat AIDS This infographic gathers 10 of the best HIV treatments in Europe’s pipeline that will help doctors worldwide fight against AIDS better than ever before. With an estimated 36.7 million people living with HIV worldwide, the search for an effective treatment that can overcome the fast evolution of the virus is rapidly gaining traction. In Europe, […] September 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2017 Scottish AI Biotech Recruits Another Pharma Partner in €37M Deal After Sanofi recruited Exscientia in a €250M deal last May, GSK has taken an interest in the startup and invested in a collaboration of its own. Artificial intelligence has been carving out a niche for itself in biotech, and Exscientia is fast establishing itself as a key player in the field. In May, the company signed a […] July 3, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2017 UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […] June 15, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email